Ependymoma Clinical Trials

24 recruitingLast updated: June 18, 2026

There are 24 actively recruiting ependymoma clinical trials across 21 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3. Top locations include Washington D.C., District of Columbia, United States, Utrecht, Netherlands, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Ependymoma Trials at a Glance

24 actively recruiting trials for ependymoma are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Washington D.C., Utrecht, and Boston. Lead sponsors running ependymoma studies include Children's National Research Institute, Centre Leon Berard, and Beijing Tiantan Hospital.

Browse ependymoma trials by phase

Treatments under study

About Ependymoma Clinical Trials

Looking for clinical trials for Ependymoma? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ependymoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ependymoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

PineoblastomaEmbryonal Tumor With Multilayered RosettesEpendymoma+3 more
Children's National Research Institute12 enrolled1 locationNCT06193759
Recruiting
Phase 1Phase 2

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

MedulloblastomaEpendymomaDiffuse Midline Glioma+1 more
Washington University School of Medicine68 enrolled3 locationsNCT06639607
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled7 locationsNCT04732065
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting

Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents

Pediatric Solid TumorEpendymoma of Brain
Institut Claudius Regaud370 enrolled1 locationNCT05151718
Recruiting
Phase 2

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

RecurrenceRefractoryHigh Grade Glioma+4 more
Clinica Universidad de Navarra, Universidad de Navarra39 enrolled2 locationsNCT07424092
Recruiting
Phase 1

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

EpendymomaAnaplastic Ependymoma
M.D. Anderson Cancer Center48 enrolled2 locationsNCT03750513
Recruiting
Phase 1Phase 2

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

GlioblastomaGliomaMedulloblastoma+1 more
National Cancer Institute (NCI)146 enrolled1 locationNCT06161519
Recruiting
Phase 2

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Neurofibromatosis type 2MeningiomaEpendymoma+2 more
Scott R. Plotkin, MD, PhD109 enrolled6 locationsNCT04374305
Recruiting
Phase 1

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Central Nervous System NeoplasmsGlioblastomaHigh Grade Glioma+4 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT05835687
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentHigh-Grade Gliomas+4 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Not Applicable

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

MedulloblastomaEpendymomaEpendymoma of Brain+3 more
University of California, San Francisco74 enrolled8 locationsNCT05057702
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Medulloblastoma RecurrentEpendymoma RecurrentATRT Recurrent+1 more
Medical University of Vienna232 enrolled22 locationsNCT01356290
Recruiting
Phase 1

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

GlioblastomaPrimary Brain TumorMedulloblastoma+1 more
Theodore S. Johnson37 enrolled1 locationNCT05106296
Recruiting
Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Central Nervous System NeoplasmsGlioblastomaOligodendroglioma+20 more
Jazz Pharmaceuticals102 enrolled1 locationNCT04541082
Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

Germ Cell TumorGliomaEpendymoma+10 more
European Organisation for Research and Treatment of Cancer - EORTC1,650 enrolled42 locationsNCT05259605
Recruiting
Phase 1

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more
Florida International University65 enrolled1 locationNCT05857969
Recruiting

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

GliomaBrain TumorsMedulloblastoma+1 more
Tata Memorial Centre200 enrolled1 locationNCT06779487